BRAF and astrocytoma (excluding glioblastoma): Considering that the statistical insignificance may be caused by the general poor prognosis of histological grade IV cases with or without these mutations, we next investigated the clinical implications of BRAF V600E and TERT promoter mutations in all histological grade II/III astroctyomas (Fig. 2b) and histological II/III astrocytomas without the H3 K27M mutation (Fig. 2c).